Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon.

Kamata Y, Minota S.

Rheumatol Int. 2014 Nov;34(11):1623-6. doi: 10.1007/s00296-014-3025-z. Epub 2014 May 1.

PMID:
24789669
2.

Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.

Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL.

Ann Rheum Dis. 2013 Oct;72(10):1696-9. doi: 10.1136/annrheumdis-2012-202836. Epub 2013 Feb 20. Review.

PMID:
23426043
3.

Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study.

Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S.

Arch Intern Med. 2012 Aug 13;172(15):1182-4. doi: 10.1001/archinternmed.2012.2271. No abstract available.

PMID:
22710940
4.

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.

De LaVega AJ, Derk CT.

Expert Opin Investig Drugs. 2009 Jan;18(1):23-9. doi: 10.1517/13543780802525100 . Review.

PMID:
19053879
5.

[Novel indications for phosphodiesterase type 5 inhibitors].

Rosenkranz S, Caglayan E, Erdmann E.

Med Klin (Munich). 2007 Aug 15;102(8):617-30. Review. German.

PMID:
17694282
6.

Phosphodiesterase inhibitors in Raynaud's phenomenon.

Levien TL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1388-93. Epub 2006 Jul 11. Review.

PMID:
16835313
7.

[Evidence-based therapy of Raynaud's syndrome].

Distler M, Distler J, Ciurea A, Kyburz D, Müller-Ladner U, Reich K, Distler O.

Z Rheumatol. 2006 Jul;65(4):285-9. Review. German.

PMID:
16804699
8.

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S.

Arch Intern Med. 2006 Jan 23;166(2):231-3.

PMID:
16432094

Supplemental Content

Loading ...
Support Center